Comparing the effectiveness of deucravacitinib and apremilast for plaque psoriasis in adults in Japan

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the real-world effectiveness of deucravacitinib compared to apremilast in adults diagnosed with plaque psoriasis in Japan. Participants will be adults aged 18 and older who are newly starting treatment with either medication, as reported by their physicians. The study will gather data on treatment outcomes and patient experiences to assess the comparative effectiveness of these two therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Japanese adult participants aged 18 years old or older
* Physician-reported diagnosis of plaque psoriasis
* Newly initiating deucravacitinib or apremilast according to the label
* Participants who have signed informed consent

Exclusion Criteria:

* Participants currently participating in or planning to participate in an interventional clinical trial
* Patients enrolled in deucravacitinib post-marketing surveillance study (ClinicalTrial.gov ID: NCT05633264)
* Previous treatment experience with the treatment of interest (e.g. patients who have history of apremilast will not be eligible to be enrolled in apremilast arm of the study and similar for deucravacitinib)

Where it's running

• Mebix. Inc.
  Minato-ku, Tokyo, Japan Recruiting
• Fukuoka University Hospital
  Fukuoka, Japan Recruiting

Study contacts

• Study coordinator: BMS Study Connect Contact Center www.BMSStudyConnect.com
• Email: Clinical.Trials@bms.com
• Phone: 855-907-3286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term safety of deucravacitinib versus ustekinumab for plaque psoriasis (PRAGMATYK)

  This study will test whether deucravacitinib or ustekinumab has better long-term safety for adults with moderate-to-severe plaque psoriasis who have cardiovascular risk factors.

  Recruiting at 323 sites Phase 3 Bristol-Myers Squibb · Birmingham, Alabama and 410 other locations · NCT07116967

• Deucravacitinib for teens with moderate to severe plaque psoriasis

  This trial will test whether deucravacitinib helps teens with moderate to severe plaque psoriasis while tracking safety and drug levels.

  Recruiting at 89 sites Phase 3 Bristol-Myers Squibb · Birmingham, Alabama and 132 other locations · NCT06979453

• Evaluating Deucravacitinib for Pediatric Plaque Psoriasis

  This study is testing a new medication called Deucravacitinib to see if it helps children and teens with moderate to severe plaque psoriasis feel better and is safe for them to use.

  Recruiting at 45 sites Phase 3 Bristol-Myers Squibb · Ciudad Autonoma de Buenos Aires, Buenos Aires and 64 other locations · NCT04772079

• How safe and well ZP9830 works in people with plaque psoriasis over 8 weeks

  This study tests whether ZP9830 is safe and tolerable in adults with plaque psoriasis for 8 weeks, with a comparison to placebo.

  Recruiting Phase 1 Zealand Pharma · Leiden, South Holland · NCT07733089

• Secukinumab retention in adults with plaque psoriasis and MASLD in Spain

  This study tests how long people with plaque psoriasis and MASLD stay on secukinumab in real-world Spain, using EMR data from several hospitals.

  Recruiting at 9 sites Novartis · Badalona, Barcelona and 8 other locations · NCT07683065

• Deucravacitinib for scarring hair loss (frontal fibrosing and central centrifugal alopecia)

  This trial will test whether taking deucravacitinib once daily for 48 weeks helps adults with frontal fibrosing alopecia or central centrifugal cicatricial alopecia.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07508488

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.